-
-
-
-
-
-
-
Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
-
-
-
-
-
-
-
Regeneron Completes Purchase of Sanofi's Stake in Libtayo® (cemiplimab)
-
-
-
-
-
-
-
CHECKMATE PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of CMPI and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
-
-
-
-
-
-
-
Regeneron (REGN) Announces U.S. Government Agreement to Purchase Additional COVID-19 Antibody Cocktail Doses
-
-
-
-
-
-
-
FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis
-
-
-
-
-
-
-
Regeneron (REGN), Sanofi (SNY) Report FDA Approval of Asthma Indication for Dupixent (dupilumab)
-
887,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All